Traveka Wealth LLC Sells 552 Shares of Novo Nordisk A/S (NYSE:NVO)

Traveka Wealth LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 6.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 8,000 shares of the company’s stock after selling 552 shares during the period. Traveka Wealth LLC’s holdings in Novo Nordisk A/S were worth $688,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of NVO. Novare Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares during the last quarter. Steel Grove Capital Advisors LLC boosted its stake in Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after acquiring an additional 86 shares during the last quarter. Benjamin Edwards Inc. grew its holdings in Novo Nordisk A/S by 2.6% during the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock worth $493,000 after acquiring an additional 87 shares during the period. Rosenberg Matthew Hamilton raised its position in shares of Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after acquiring an additional 94 shares during the last quarter. Finally, Burns J W & Co. Inc. NY boosted its position in shares of Novo Nordisk A/S by 1.9% in the 3rd quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after purchasing an additional 100 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $84.43 on Tuesday. The company has a fifty day moving average price of $99.84 and a 200 day moving average price of $118.61. The firm has a market cap of $378.88 billion, a PE ratio of 27.32, a PEG ratio of 1.37 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $81.50 and a 1-year high of $148.15.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.